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Abstract No ligand has hitherto been designated for the Eph
receptor tyrosine kinase family member, EphB6. Here, expres-
sion of an EphB6 ligand in the pro-B leukemic cell line, Reh, is
demonstrated by binding of soluble EphB6-Fc fusion protein to
the Reh cells. The ligand belongs to the subgroup of membrane
spanning ligands, as suggested by the fact that phosphatidylino-
sitol-specific phospholipase C treatment did not abrogate binding
of EphB6-Fc. Two transmembrane Eph receptor ligands, ephrin-
B1 and ephrin-B2, were identified in Reh cells. Analysis of
EphB6-Fc fusion protein binding to ephrin-B1 or ephrin-B2
transfected COS cells revealed a high-affinity saturable binding
between EphB6-Fc and ephrin-B2, but not with ephrin-B1. In
mice, EphB6 has previously been shown to be expressed in
thymus. Here, we show expression of EphB6 in human thymus,
as well as the expression of ephrin-B2 in both human and mouse
thymus. We conclude that ephrin-B2 may be a physiological
ligand for the EphB6 receptor.
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1. Introduction
Receptor tyrosine kinases and their ligands play a critical
role in regulation of cellular survival, proliferation and di¡er-
entiation [1]. On the basis of predicted structural homologies,
sequence conservation and similarity of ligands, receptor ty-
rosine kinases have been assigned to several subclasses [2].
The largest family of receptor tyrosine kinases, the Eph re-
ceptors, consists of at least 14 distinct members highly con-
served from Caenorhabditis elegans to man (reviewed in [3^6]).
Recently, a family of at least eight membrane-bound ligands
for Eph receptors, termed ephrins, has been identi¢ed (re-
viewed in [7]). The ephrins share between 23 and 56% identity
at the amino acid level and display promiscuous binding to
Eph receptors [8]. The ligands can be divided into two classes,
those that are attached to the cell membrane by a glycosyl-
phosphatidylinositol (GPI) linkage, ephrin-A1^A5, and those
that are membrane spanning molecules, ephrin-B1^B3. The
cytoplasmic domains of the transmembrane ligands ephrin-
B1 and ephrin-B2 have been shown to be phosphorylated
on tyrosine residues after contact with their receptors, suggest-
ing that the transmembrane ligands have receptor-like intrin-
sic signaling potential [9,10].
The biological function of the interaction of Eph receptors
with their corresponding ligands is being unveiled in several
di¡erent cell systems. Signaling via Eph receptors and ephrins
has been implicated in neural and epithelial morphogenesis
[11], axon guidance and fasciculation [12^16], control of neu-
ral crest cell migration [17^20], formation of rhombomere
boundaries [21], inhibition of cell^cell adhesion [22], angio-
genesis [23] and morphogenesis of capillary beds [24]. In ad-
dition, deregulated expression of the Eph receptors or ligands
may play a role in malignant transformation of cells [25^28].
Except for the EphB5 and EphB6 receptors, at least one li-
gand has been de¢ned for each member of the Eph receptor
family [8,29].
In this study we have identi¢ed a candidate ligand for the
EphB6 receptor.
2. Materials and methods
2.1. Cell lines
All hematopoietic cell lines were grown in RPMI 1640 supple-
mented with 10% FBS. The monkey cell line COS-1 was grown in
DMEM supplemented with 5% FBS. All cell lines were grown at 37‡C
in a humidi¢ed atmosphere with 5% CO2.
2.2. Construction of vectors
For this study we generated expression vectors for the production
of EphB6, EphB1 and CD19 (short), all as fusion proteins with the Fc
part of mouse IgG2b. The fusion partner includes, in addition to the
CH2 and CH3 domains, also the hinge region of mouse IgG2b (plas-
mid denoted pcDNA1-Fc). EphB6 ectodomain cDNA was generated
by PCR on reverse transcribed ¢rst strand cDNA (RT-PCR, HPB-
ALL cell line mRNA), using primers that ampli¢ed the sequence
corresponding to the region encoding amino acids 1^567 in the pub-
lished EphB6 sequence [30], and further cloned in-frame with the Fc
part of mouse IgG2b in pcDNA1-Fc. The recognition sequences of
the restriction enzymes HindIII and BglII were included in the EphB6
forward and reverse primer respectively, for cloning purposes. EphB1
ectodomain cDNA was generated by RT-PCR (brain mRNA), using
primers that ampli¢ed the sequence corresponding to the region en-
coding amino acids 1^538 [31] and further cloned in-frame with the Fc
part of mouse IgG2b in pcDNA1-Fc. The recognition sequences of
the restriction enzymes HindIII and BamHI were included in the
EphB1 forward and reverse primer respectively, for cloning purposes.
The sequence encoding the 51 N-terminal amino acids of the CD19
mRNA was ampli¢ed from a CD19 cDNA clone [32] and further
cloned in-frame with mouse Fc part of IgG2b in pcDNA1-Fc. For
cloning purposes, the recognition sequences of the restriction enzymes
HindIII and BamH1 were included in the CD19 forward and reverse
primer respectively.
Ephrin-B1 and ephrin-B2 cDNAs were PCR ampli¢ed from Reh
¢rst strand cDNA using primers that ampli¢ed the open reading
frame. Ephrin-B1 was ampli¢ed using primers that included amino
acids 1^346 [33] and further cloned into the pcDNA1 vector (Invitro-
gen, CA, USA) using the restriction sites HindIII and XhoI included
in the primers. Ephrin-B2 was ampli¢ed using primers that included
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amino acids 1^333 [34] and further cloned into the pcDNA1 vector
using the restriction sites HindIII and XhoI included in the primers.
All constructs were con¢rmed by sequencing.
2.3. Identi¢cation of ephrins by degenerate PCR
Degenerate primers were synthesized based on amino acids that are
highly conserved among ephrin-B members. The forward primers (F)
were directed against the sequence KFQE (amino acids nos. 113^116
in ephrin-B2) and the reverse primers (R) were directed against the
sequence CPHYE (amino acids nos. 301^305 in ephrin-B2). The se-
quences were: (F) 5P GGG ATC CAA RTT YCA RGA RT and (R)
5P GGA ATT CTT YTC RTA RTG NGG RCA (N for A/C/G/T, R
for A/G, Y for C/T). First strand cDNA generated from Reh cells was
used for the ampli¢cation. The PCR conditions were as follows: 42
cycles of 94‡C for 30 s, 37‡C for 40 s and 65‡C for 100 s with the
primers F and R. The resulting PCR product was cloned in T-vector
(Promega, Madison, WI, USA) and individual clones were sequenced.
2.4. Transfection of COS cells and production of fusion proteins
COS cells were transfected for binding analysis and for fusion pro-
tein production. Brie£y, COS cells were transfected using a DEAE-
dextran protocol [35] with 1 Wg/ml plasmid in the transfection me-
dium. For binding analysis, the cells were detached from the plates
with 1 mM EDTA in PBS 2 days post-transfection.
Production and secretion of fusion proteins were veri¢ed by 35S-
methionine labeling of transfected COS cells, and the radiolabeled
fusion proteins were subsequently puri¢ed from the culture superna-
tant by protein-G puri¢cation and analyzed by SDS^PAGE. For
larger scale protein production, transfected COS cells were grown in
225 cm2 culture £asks (50^100 ml medium) and fusion proteins were
a⁄nity puri¢ed from the culture supernatants using a protein-G col-
umn.
2.5. Cell staining
Reh cells were incubated with the fusion proteins EphB1-Fc,
EphB6-Fc and CD19-Fc (2.5 Wg/ml) for 1 h at 4‡C. The cells were
then washed twice and stained with a phycoerytrin-labeled (PE) anti-
mouse Ig polyclonal antibody (Ig-RPE, Southern Biotechnology As-
sociates, Birmingham, AL, USA) directed to the Ig tail of the fusion
proteins. 104 cells were analyzed by £ow cytometry.
COS cells transfected with either ephrin-B1 or ephrin-B2 cDNAs
were incubated with EphB1-Fc, EphB6-Fc and CD19-Fc fusion pro-
teins. The cells were washed and stained with a PE-labeled anti-mouse
Ig polyclonal antibody. 104 cells were analyzed by £ow cytometry.
2.6. Phosphatidylinositol-speci¢c phospholipase C (PI-PLC) treatment
of Reh cells
1U106 Reh cells were treated with 1.1 U/ml PI-PLC (Roche Diag-
nostic, Germany) for 2 h at 37‡C in RPMI 1640, followed by washing
with PBS. The cells were incubated with either CD19-Fc or EphB6-Fc
followed by staining with PE conjugated anti-mouse antibody or anti-
CD24-FITC conjugated antibody (Pharmingen, CA, USA). Anti-
CD24 serves as a positive control for the PI-PLC treatment. 104 cells
were analyzed by £ow cytometry.
2.7. Scatchard plot analysis
COS cells were transiently transfected with ephrin-B2 expression
plasmid, and used in the binding assays 2 days post-transfection.
The EphB6-Fc fusion protein was initially bound to the transfectants
(1 h, 4‡C) followed by binding of a ¢xed amount of a 125I-labeled
anti-mouse antibody (1 h, 4‡C). Ephrin-B2 transfectants were ana-
lyzed for binding of di¡erent concentrations of EphB6-Fc, ranging
from 2 Wg/ml to 0.0025 Wg/ml. To calculate the molar concentration
of EphB6-Fc fusion protein, a molecular mass of 190 kDa was as-
sumed. Saturating amounts of 125I-labeled anti-mouse immunoglobu-
lin were used to detect the binding of EphB6-Fc. Cell-bound 125I-
labeled antibody was quanti¢ed in a Packard autogamma counter.
Non-speci¢c binding of 125I-labeled antibody was assayed in the ab-
sence of EphB6-Fc, as well as in the presence of a 200-fold molar
excess of unlabeled antibody. Both methods gave similar estimates for
the non-speci¢c binding, and the ¢gure shows the speci¢c binding,
obtained by subtracting non-speci¢c binding from total binding.
The speci¢c binding data (total binding minus non-speci¢c binding)
were analyzed by non-linear curve ¢tting using Microsoft Excel 97
with the Solver add-in, and were best ¢t to the equation
Y = Bmax*X/(Kd+X), indicating the presence of only one type of bind-
ing sites. The observed data and the theoretical curve were plotted
according to Scatchard [36] using Microsoft Excel 97 (inset).
2.8. Northern blot analysis
Total RNA was extracted from mouse tissues (Balb/c) by standard
guanidine thiocyanate methods and mRNA was isolated from tissues
using oligo-dT Dynabeads (Dynal, Norway) as previously described
[37]. 2 Wg mRNA was size-fractionated on a 1% agarose formaldehyde
denaturing gel and transferred to nylon membranes. A commercially
available multiple tissue Northern blot was purchased from Clontech
(Immune blot 1; Clontech, CA, USA). Prehybridization (1 h) and
hybridization were performed in hybridization bu¡er (5USSPE,
10% dextran sulphate, 0.1% SDS, 50% formamide, 100 Wg/ml sheared
salmon sperm DNA) at 42‡C, and the membranes were hybridized
overnight with 32P-dCTP-labeled EphB6 cDNA probe, ephrin-B2
cDNA probe or with a control L-actin probe. After hybridization,
the membranes were washed under high stringency in 0.2 SSC/0.1%
SDS at 65‡C.
Fig. 1. A: Production and secretion of fusion proteins in transfected
COS cells. COS cells were transfected in 6-well plates and the cells
were labeled overnight with 35S-methionine in methionine-free me-
dium 2 days post-transfection. Fusion proteins were isolated from
the culture medium by incubation with protein-G Sepharose beads
and separated by SDS^PAGE under denaturing conditions. Lane 1,
radioactive molecular weight standard; lane 2, mock transfected
COS cells; lane 3, COS cells transfected with CD19-Fc plasmid;
lane 4, COS cells transfected with EphB1-Fc plasmid; lane 5, COS
cells transfected with EphB6-Fc plasmid. The protein bands occur-
ring in lanes 3^5 are the CD19-Fc fusion protein, the EphB1-Fc fu-
sion protein and the EphB6-Fc fusion protein, respectively. B: Flow
cytometry analysis on fusion protein binding to the Reh cell line.
Reh cells were incubated with either CD19-Fc, EphB1-Fc or
EphB6-Fc fusion proteins (2.5 Wg/ml) followed by staining with a
PE conjugated anti-mouse antibody.
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3. Results and discussion
The aim of this study was to identify a candidate ligand for
the EphB6 receptor, and to further apply this knowledge in
studies of the interaction of the EphB6 receptor with its ligand
in hematopoietic tissues. Therefore, a fusion protein of the
ectodomain of EphB6 with mouse IgG2b-Fc was generated
and applied in binding studies. Corresponding fusion proteins
of the ectodomain of EphB1 and of the 51 N-terminal amino
acids of the CD19 protein were also produced. Plasmids en-
coding the fusion proteins were transfected into COS cells,
and fusion proteins were isolated from the culture superna-
tant. Production and secretion of fusion proteins were veri¢ed
by 35S-methionine-labeling of transfected COS cells followed
by SDS^PAGE. The molecular masses of both EphB1-Fc and
EphB6-Fc fusion proteins were approximately 100 kDa, and
the CD19-Fc fusion protein was approximately 45 kDa (Fig.
1A).
To test the binding characteristics of the fusion proteins, a
panel of hematopoietic cell lines were screened for cell surface
binding of the EphB6-Fc fusion protein including the B cell
lines JKB-2, Tom-1, Reh, Nalm-6, Daudi and Rael, the T cell
lines JM, Jurkat and JY, the myeloid cell lines KG1-A and
HL60, and the erythroid cell line K562. To this end, only one
cell line, the leukemic pro-B cell line Reh, bound the EphB6-
Fc fusion protein as shown in Fig. 1B. Therefore, this cell line
was used in the following studies to identify a candidate
EphB6 ligand. Fig. 1B also shows that the EphB1-Fc fusion
protein binds to the Reh cell line. No binding was observed
for the CD19-Fc fusion protein which serves as a negative
control.
The ligands of the Eph receptors are divided in two classes,
ephrin-A1 to ephrin-A5 that are bound to the cell membrane
by a GPI linkage, and ephrin-B1 to ephrin-B3 that are mem-
brane spanning molecules [8]. Treatment of cells with phos-
phatidylinositol-speci¢c phospholipase C (PI-PLC), which re-
leases GPI-linked proteins from their lipid moiety, can be used
to test if a given Eph receptor binds to a transmembrane or
GPI-linked ligand [38]. As shown in Fig. 2C, the treatment of
Reh cells with PI-PLC had minimal e¡ect on the EphB6-Fc
fusion protein binding, while a signi¢cant reduction in the
GPI-linked surface protein CD24 [39] was observed under
the same treatment (Fig. 2D) demonstrating that the assay
was functional. We conclude from this observation that the
EphB6 receptor most likely binds to a member of the trans-
membrane class of Eph ligands (ephrin-B). This veri¢es the
assumption made by the Eph Nomenclature Committee who
has placed the EphB6 receptor in the subclass of receptors
(EphB1^B6) that preferentially bind transmembrane ligands
based on the relatedness of their extracellular domains [40].
The other Eph receptor subgroup (EphA1^A8) preferentially
binds GPI-linked ephrin ligands.
Based on the results with PI-PLC treatment, we established
a PCR-based screen to identify the transmembrane ligand(s)
that are expressed in the Reh cell line. The intracellular do-
main of the three transmembrane ligands, ephrin-B1^B3, are
highly conserved, in particular at the 33 most C-terminal ami-
no acids [41]. In addition, there are conserved amino acid
stretches in the extracellular domain. Degenerated oligonu-
cleotides were generated based on a conserved sequence in
the extracellular domain, amino acids KFQE and a conserved
region in the intracellular domain, CPHYE. The primers were
employed in RT-PCR using Reh mRNA. The resulting prod-
uct was cloned and subsequently sequenced. Initially, DNA
from ¢ve separate clones was sequenced. Four of the sequen-
ces were identical to ephrin-B1 and one sequence was identical
to ephrin-B2. No ephrin-B3 sequence was identi¢ed. Northern
blot analysis con¢rmed the expression of both ephrin-B1 and
ephrin-B2 in the Reh cells (data not shown).
RT-PCR analysis of Reh cell mRNA with ephrin-B3-spe-
ci¢c primers revealed no expression of ephrin-B3 in these cells
(data not shown). Based on this information, cDNAs, includ-
ing the complete open reading frames of both ephrin-B1 [33]
and ephrin-B2 mRNA [34], were ampli¢ed by RT-PCR from
Reh cell mRNA and further cloned into the expression vector
pcDNA1 for transfection and subsequent binding analysis.
Ephrin-B1 and ephrin-B2 cDNAs in pcDNA1 were trans-
fected into COS cells and EphB6-Fc binding was evaluated by
£ow cytometry. As shown in Fig. 3A, binding of EphB6-Fc to
the ephrin-B2 transfectants was demonstrated in the concen-
tration range of 2.5 Wg/ml to 0.05 Wg/ml of EphB6-Fc fusion
protein. In contrast, binding to the ephrin-B1 transfectants
was much weaker and only observed at the highest concen-
tration of EphB6-Fc (2.5 Wg/ml, Fig. 3B) as revealed by both
fewer positive cells and less £uorescence intensity compared
with ephrin-B2. No binding was observed to the ephrin-B1
transfectants at lower EphB6-Fc concentrations (0.5^0.05
Wg/ml), in contrast to the binding observed to the ephrin-B2
transfectants (Fig. 3). Both the ephrin-B1 and the ephrin-B2
ligands have previously been shown to bind to the EphB1
receptor with approximately the same binding a⁄nity [8].
We also found comparable binding of EphB1-Fc fusion pro-
tein to both the ephrin-B1 and ephrin-B2 transfectants (Fig.
3B), in the range of 1.25 to 0.02 Wg/ml. To con¢rm that the
ephrin-B2 ligand bound to the EphB6 receptor, we demon-
strate that ephrin-B2-Fc fusion protein bound to COS cells
transfected with full length EphB6 cDNA (data not shown).
Previously, the ephrin-B2 ligand has been shown to bind
the receptors EphB1, EphB2, EphB3 and EphB4 and subse-
quently induce auto-phosphorylation of these receptors [8,42^
44]. The ephrin-B1 ligand also binds and induces auto-phos-
phorylation of the EphB1, EphB2, EphB3 receptors [11], but
it binds with very weak a⁄nity to EphB4 [44]. In vitro clus-
Fig. 2. Flow cytometry analysis on PI-PLC treated Reh cells. The
cells were incubated with either CD19-Fc (A) or EphB6-Fc (C) fol-
lowed by PE conjugated anti-mouse antibody (A and C), irrelevant
Ig-FITC (B) or anti-CD24 FITC conjugated (D). Dotted lines repre-
sent PI-PLC treated cells, bold line represents untreated cells.
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tering of ephrin-B1 ligand does not induce auto-phosphoryla-
tion of EphB4 like it does for EphB1^B3, but intriguingly,
coculturing of EphB4 and ephrin-B1 transfectants leads to
auto-phosphorylation of EphB4, although to a lower extent
than coculturing with the ephrin-B2 ligand [44]. It remains
unclear if ephrin-B1 is a physiological ligand for the EphB4
receptor. Here we show that EphB6, like EphB4, preferen-
tially binds to ephrin-B2 in comparison to ephrin-B1.
In addition, we have performed binding studies of EphB6-
Fc to COS cells transfected with two members of the ephrin-A
class of ligands (ephrin-A2 and ephrin-A4) showing no bind-
ing to these ligands (data not shown).
Further, to evaluate the a⁄nity of the interaction between
EphB6 and ephrin-B2, we performed quantitative analysis of
the binding between EphB6-Fc fusion protein and COS cells
expressing ephrin-B2, using a two-step screening protocol [45].
COS cells were transfected with ephrin-B2 expression plasmid,
and used in the binding assays 2 days post-transfection. The
EphB6-Fc fusion protein was initially bound to the transfec-
tants followed by binding of a ¢xed amount of a 125I-labeled
anti-mouse antibody. Our calculations are based on the as-
sumption that one molecule of EphB6-Fc was bound per li-
gand molecule at saturation, and that one molecule of 125I-
labeled antibody was bound per EphB6-Fc molecule. Ephrin-
B2 transfectants were analyzed for binding of di¡erent con-
centrations of EphB6-Fc. Saturating amounts of 125I-labeled
Fig. 3. Flow cytometry analysis on binding of EphB6-Fc or EphB1-Fc fusion proteins to ephrin-B1 and ephrin-B2 transfected COS cells. The
cells were incubated with either EphB6-Fc or EphB1-Fc followed by staining with PE conjugated anti-mouse antibody. Dead cells were ex-
cluded by propidium iodide staining. A: Flow cytometry analysis on EphB6-Fc binding to ephrin-B2 (left panel) and ephrin-B1 (right panel)
transfected COS cells, using decreasing concentrations of EphB6-Fc fusion protein. The upper panel shows binding of the negative control pro-
tein (CD19-Fc) to the transfected cells. B: Flow cytometry analysis of EphB1-Fc binding to ephrin-B2 (left panel) and ephrin-B1 (right panel)
transfected COS cells, using decreasing concentrations of EphB1-Fc fusion protein. The upper panel shows binding of the negative control pro-
tein (CD19-Fc) to the transfected cells. The Y axis shows the cell counts.
Fig. 4. Quantitative analysis of the binding between EphB6-Fc fu-
sion protein and COS cells expressing ephrin-B2. COS cells were
transiently transfected with ephrin-B2 expression plasmid, and used
in the binding assays 2 days post-transfection. Binding of the
EphB6-Fc fusion protein was assayed as described in Section 2. In-
sets show Scatchard representations of speci¢c binding. The ¢gure
shows one representative experiment of three, yielding similar re-
sults.
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anti-mouse immunoglobulin were used to detect the binding
of EphB6-Fc to COS cells. The speci¢c binding data were
analyzed by non-linear curve ¢tting, and were best ¢t to the
equation Y = Bmax*X/(Kd+X), indicating the presence of only
one type of binding sites. Fig. 4 shows the speci¢c binding
data as well as the Scatchard [36] transformation of the ob-
served data and the theoretical curve, for illustration (Fig. 4,
inset) of one of three experiments yielding similar results. The
results indicate a dissociation constant (Kd) of 0.5^1 nM,
which is comparable to data presented for binding of other
ligands to the Eph receptors [8,46,47].
A true receptor-ligand interaction would imply binding of
the ligand followed by auto-phosphorylation of the receptor
leading to intracellular signaling. In both mouse and man the
intracellular tyrosine kinase domain of EphB6 has been shown
to be defective [48,30] and therefore such a ligand interaction
would not induce auto-phosphorylation by the receptor. Pre-
viously, it has been shown that also the transmembrane ephrin
ligands can be phosphorylated on tyrosine residues after re-
ceptor interaction [9,10]. Thus, it is proposed that transmem-
brane ligands of Eph receptors act not only as conventional
RTK ligands, but also as receptor-like signaling molecules,
suggesting that transmembrane ligands and their receptors
mediate bidirectional signaling. In the case of the EphB6 re-
ceptor one can speculate that, due to the defective kinase
domain, intracellular signaling after receptor-ligand interac-
tion is not bidirectional, but unidirectional and occurs only
in the cells carrying the membrane spanning ligand. In our
hands, we have neither succeeded in detecting phosphoryla-
tion of the ephrin-B2 ligand after interaction with EphB6-Fc,
nor of ephrin-B1 after EphB1-Fc interaction as previously
shown by others [9,10].
Lastly, we performed EphB6 and ephrin-B2 mRNA expres-
sion analysis in hematopoietic tissues. Human EphB6 expres-
sion in such tissues has previously not been demonstrated. We
show here that, as in mice [30], this receptor is strongly ex-
pressed in human thymus and barely detectable in other hem-
atopoietic tissues (Fig. 5A). Furthermore, ephrin-B2 mRNA
was detected in human spleen and lymph node, and with
weaker expression in thymus, bone marrow and fetal liver
(Fig. 5B). A di¡erent expression pattern was observed in
mice, with high ephrin-B2 mRNA level in thymus (compara-
ble to brain) and absence of ephrin-B2 mRNA in spleen and
bone marrow (Fig. 5C). Thus, in both man and mouse, the
EphB6 receptor and its candidate ligand, ephrin-B2, can both
be found in thymus, although the ephrin-B2 expression in
mouse thymus is more pronounced than in humans. We there-
fore speculate that this receptor-ligand couple serves a phys-
iological role in thymus.
In conclusion, we report here that ephrin-B2 is a candidate
ligand for the EphB6 receptor. The interaction of EphB6 and
ephrin-B2 was shown to be of high a⁄nity by Scatchard anal-
ysis. EphB6 has a limited expression in both human and
mouse tissues, and in hematopoietic tissues expression is
mainly in thymus. Ephrin-B2 expression is also observed in
thymus, although weak in humans. The next challenge in the
study of the biological function of this receptor-ligand inter-
action will be to de¢ne the cell populations in the micro-en-
vironment, where these genes are expressed, for further func-
tional analysis.
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